Hepatitis C And Injecting Drug Use: Impact Costs And Policy Options
Office for Official Publications of the European Communities, 2004 - Medical - 389 pages
Established in 1993, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is an EU agency which collects and disseminates comparable evidence-based data on drugs and drug addiction in Europe. This publication is the seventh in the series of scientific monographs and contains papers on the topic of hepatitis C and injecting drug users. It is divided into four parts dealing with: natural history, treatment, quality of life, epidemiology and prevention issues; models of hepatitis C infection, injecting drug use and policy options; healthcare costs and wider costs of drug use; cost-effectiveness of needle and syringe programmes and methadone maintenance.
40 pages matching patients with chronic in this book
Results 1-3 of 40
What people are saying - Write a review
We haven't found any reviews in the usual places.
Natural history treatment and prevention
Recent developments in hepatitis C diagnostics
16 other sections not shown
24 weeks 48 weeks analysis antibodies antiviral treatment assessment average blood-borne diseases Chapter chronic hepatitis cirrhosis clinical combination therapy consumption cost-effectiveness costs of drug countries discounted drug addiction drug treatment drug-related economic evaluation effects EMCDDA epidemic Epidemiology estimates factors fibrosis Figure genotype harm reduction HCV infection HCV prevalence HCV RNA healthcare costs hepatitis C infection hepatitis C virus hepatocellular carcinoma Hepatology HIV prevention IDUs illicit drugs impact incidence indirect costs individuals infectious diseases injecting drug users injectors intangible costs interferon alpha interferon and ribavirin interventions Journal of Medicine liver disease Medical methadone method million mortality needle and syringe needle sharing NSPs parameters patients with chronic PEG interferon pharmaco-economic Postma Poynard production losses programmes Public Health reduce relapse ribavirin risk behaviour social costs studies substance abuse symptoms Tragler transmission treatment costs virus infection Wiessing willingness-to-pay approach Wong